Literature DB >> 16862315

In vitro susceptibility to antifungal agents of environmental Cryptococcus spp. isolated in the city of Ribeirão Preto, São Paulo, Brazil.

Reginaldo dos Santos Pedroso1, Joseane Cristina Ferreira, Regina Celia Candido.   

Abstract

Infections by Cryptococcus strains other than C. neoformans have been detected in immunocompromised patients. Of these strains, three are considered human pathogens: C. albidus, C. laurenttii, and C. uniguttulatus. This study deals with the in vitro susceptibility of Cryptococcus to drugs such as amphotericin B, itraconazole, fluconazole, and 5-fluorocytosine. Environmental Cryptococcus isolates (50) distributed as follows: C. neoformans var. neoformans (16), C. albidus (17), C. laurentii (14), and C. uniguttulatus (3) were evaluated by the micro and macrodilution techniques, according to EUCAST and NCCLS recommendations, respectively. Considering both methodologies the respective minimal inhibitory concentrations (MIC) were 0.125 and 2 microg/ml for amphotericin B, 0.06 and 8 microg/ml for itraconazole, and 0.5 and more than 64 microg/ml for fluconazole and 5-fluorocytosine. Agreement percentages for the two methodologies were 100% for amphotericin B and fluconazole for all the strains tested. For itraconazole, the agreement percentage was 81.3% in the C. neoformans strain and 100% for all the others. All species had a agreement percentage of 94.1 to 100% when susceptibility to 5-fluorocytosine was tested. It is concluded that environmental isolates of C. neoformans var. neoformans, C. albidus, C. laurentii, and C. uniguttulatus may show high MICs against certain drugs, suggesting in vitro primary resistance to the antifungals tested.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16862315     DOI: 10.1590/s0074-02762006000300002

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  4 in total

1.  Antifungal susceptibility, enzymatic activity, PCR-fingerprinting and ITS sequencing of environmental Cryptococcus laurentii isolates from Uberaba, Minas Gerais, Brazil.

Authors:  Kennio Ferreira-Paim; Leonardo Andrade-Silva; Delio Jose Mora; Eliane Lages-Silva; André Luiz Pedrosa; Paulo Roberto da Silva; Anderson Assunção Andrade; Mario León Silva-Vergara
Journal:  Mycopathologia       Date:  2011-11-25       Impact factor: 2.574

2.  Cryptococcus laurentii biofilms: structure, development and antifungal drug resistance.

Authors:  K Ajesh; K Sreejith
Journal:  Mycopathologia       Date:  2012-09-01       Impact factor: 2.574

3.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.

Authors:  M A Pfaller; D J Diekema; D L Gibbs; V A Newell; H Bijie; D Dzierzanowska; N N Klimko; V Letscher-Bru; M Lisalova; K Muehlethaler; C Rennison; M Zaidi
Journal:  J Clin Microbiol       Date:  2008-11-12       Impact factor: 5.948

4.  Phenotypes Associated with Pathogenicity: Their Expression in Arctic Fungal Isolates.

Authors:  Laura Perini; Diana C Mogrovejo; Rok Tomazin; Cene Gostinčar; Florian H H Brill; Nina Gunde-Cimerman
Journal:  Microorganisms       Date:  2019-11-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.